Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
2006
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Natural History of Small Untreated Hepatocellular Carcinoma in Cirrhosis: A Multivariate Analysis of Prognostic Factors of Tumor Growth Rate and Patient Survival
1992
Hepatocellular carcinoma
2003 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)
2003
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Hepatocellular carcinoma
2018 Standout
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
2001 Standout
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
1998
A Rationale for the Reinitiation of Adjuvant Tamoxifen Therapy in Women Receiving Fewer than 5 Years of Therapy
2002
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
2001
Hepatocellular carcinoma
2012 Standout
Prognosis prediction and staging
2014
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer
1995
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer
2001
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
1999
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
1997
Measuring inconsistency in meta-analyses
2003 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
1997
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
1996 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Treatment of hepatocellular carcinoma in patients with cirrhosis
1997
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2005 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
2002 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Annual hazard rates of recurrence for breast cancer after primary therapy.
1996
Adjuvant tamoxifen: how long before we know how long?
1998
Assessment of CA 15.3, CEA and TPA Concentrations during Monitoring of Breast Cancer
2000
Does tumour dormancy offer a therapeutic target?
2010
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids
1995 Standout
Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
1999
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
1991
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
1992
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Preservation of Fertility in Patients with Cancer
2009 Standout
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
2005
Cancer of the Ovary
2004 Standout
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
1994
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma
1982
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
2006
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Nonviral Vectors for Gene Delivery
2008 Standout
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
1986
Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
1989
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide
1987 Standout
Phase II trial of VP-16-213 in advanced ovarian carcinoma
1985
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors
1994
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy
1982
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
2001
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2004 Standout
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
1988
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Tamoxifen for early breast cancer: an overview of the randomised trials
1998 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
VP16-213 as a single agent in advanced testicular tumors
1980
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Works of H. C. Falkson being referenced
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
1992
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
1996
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
1990
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
1991
A Randomized Trial of Mitomycin-C (M) Versus Mitomycin-C Plus High-Dose Medroxyprogesterone Acetate (MMPA) in the Treatment of Patients with Advanced Breast Cancer
1993
Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast Cancer
1996
Dibromodulcitol and Adriamycin ± tamoxifen in advanced breast cancer*
1982
Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group B
1979
A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213
1975
Prognostic factors for survival in hepatocellular carcinoma.
1988
FLUOROURACIL AND RADIOTHERAPY IN GASTROINTESTINAL CANCER
1969
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
1986
Carcinoembryonic antigen in patients with breast cancer.An adjunctive tool to monitor response and therapy
1978